New study compares the ability of three proton pump inhibitors to control stomach acid
The annual Digestive Disease Week (DDW) presented the analysis of clinical trial including patients taking three proton pump inhibitors (PPIs) to control stomach acid. This inquiry examined traditional NSAIDs (non-steroidal anti-inflammatory drugs), such as Esomeprazole magnesium (NEXIUM) drug, Lansoprazole (Prevacid), and generic Pantoprazole (Protonix), and selective COX-2 inhibitors.
This research required a condition of daily, prescription-strength doses of a COX-2 or nonselective NSAID for at least one month. 77 participants were divided into three groups, which received the study drugs – Esomeprazole 40 mg, Lansoprazole 30 mg or Pantoprazole 40 mg in a different sequence. Five days of taking oral doses were followed by a 10-day break. On day five of each treatment period, the specialists evaluated the percent of time gastric pH in patients.
The results showed that Esomeprazole tablets maintained a pH of greater than 4.0 for 17.8 hours (74.3 percent) of the 24-hour period while Lansoprazole capsules maintained it for 15.9 hours (66.4 percent, P=.0003)) and Pantoprazole tablets for 14.6 hours (60.7 percent, P<.0001).
It is known that the most common use of NSAIDs is gastroduodenal injury – gastric erosions or stomach ulcers, and nearly 70 percent of people over the age of 65 take NSAIDs at least once a week and approximately half of them take seven doses or more per week.
Professor of Medicine, Vice Head for Clinical Affairs, Department of Medicine, University of Illinois at Chicago Jay L. Goldstein conducted the study that compared the ability of three proton pump inhibitors to control stomach acid. The lead investigator of the study, Mr. Goldstein, found out that acid control can reduce the risk for stomach ulcers and that proton pump inhibitors provide patients with pain and inflammation relief.
